Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 4Osteosarcoma 2Neoplasms 2Chondrosarcoma 2Uterine Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Adenoviridae Infections 1

Interventions

Doxorubicin 17Cyclophosphamide 16Ifosfamide 11fludarabine 9Radiotherapy 8tazemetostat 5pembrolizumab 4pazopanib 4Gemcitabine 4pegfilgrastim 3cixutumumab 3Trabectedin 3Radiation 3Imatinib Mesylate 3Filgrastim 3Docetaxel 3Dacarbazine 3sargramostim 2liposomal doxorubicin 2fludarabine phosphate 2brostallicin 2aldesleukin 2X-Rays 2Sunitinib 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Quality of Life 2Nivolumab 2Molecular Diagnostic Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × Immune Checkpoint Inhibitors × Sarcoma × Clear all
NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Baylor College of Medicine

Phase 1 Recruiting
25 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡